Jump to main content
Topic: Drug Pricing
-
Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection
Read More
-
Fact Check: Time to Market for New Drugs in U.S. Versus Other Countries
Read More
-
Abandon Biosimilars as Biologics are Natural Monopolies
Read More
-
Impact of President’s Budget and Point of Sale Rebate Proposal for Part D: 10 Year Projection
Read More
-
The “Netflix Model” of Financing Hepatitis C Treatment
Read More
-
Cardiovascular Drugs Not Price Aligned with Value in US
Read More
-
Spending On Prescription Drugs In The US: Where Does All The Money Go?
Read More
-
DPL responds to HHS Blueprint (May 16, 2018)
Read More
-
Impact of President Trump’s Proposed 340B Hospital Eligibility Threshold
Read More
-
Outcomes-Based Drug Contracts Do Not Move Us Closer to Value
Read More